Global Multiplex Detection Immunoassays Market Driven by Demand for Clinical Diagnostic Applications
By LabMedica International staff writers Posted on 18 Oct 2022 |
Multiplex detection immunoassays are increasingly being used in a wide range of applications, including infectious disease testing, food contamination testing, veterinary disease testing, and R&D activities. Multiplex immunoassays provide sufficient analytical performance to evaluate serum biomarkers that complement each other in the detection of a larger number of patient samples. The use of differentially detectable beads of different regions enables simultaneous identification and quantification of multiple analytes in the same sample allowing the individual immunoassays to be multiplexed. The global multiplex detection immunoassays market was valued at USD 1.8 billion in 2020 and is projected to register a CAGR of 9.7% during the forecast period 2022 to 2030 to hit around USD 3.7 billion by 2030, driven mainly by the increasing demand for multiplex detection immunoassays for clinical diagnosis.
These are the latest findings of Nova One Advisor (Cleveland, OH, USA), a market research and consulting organization.
In terms of assay type, the planar assay segment accounted for the highest share of the global multiplex detection immunoassays market in 2020 and is anticipated to expand at a high CAGR during the forecast period, owing to a rise in the need and demand for diagnosis by patients. Based on technique, the protein-based techniques segment held a significant share of the global multiplex detection immunoassays market in 2020. In terms of application, the research & development segment accounted for a major share of the global multiplex detection immunoassays market in 2020.
Geographically, North America held a major share of the global multiplex detection immunoassays market in 2019 due to its highly structured healthcare industry, presence of key players in the region and their growth strategies. Rising awareness about benefits of procedures and increase in healthcare expenditure are likely to propel the growth of the multiplex detection immunoassays market in North America. Asia Pacific held the second-largest share of the global multiplex detection immunoassays market in 2019, driven by rising prevalence of chronic diseases and a well-developed healthcare sector in the region. The multiplex detection immunoassays market in Asia Pacific is likely to grow at a rapid pace during the forecast period on the back of an increase in product approvals, rising prevalence of cardiovascular diseases, and surge in awareness leading to routine checkups and diagnosis.
Related Links:
Nova One Advisor
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus